MLTX (MoonLake Immunotherapeutics) Current Accrued Expense: $22.15 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLTX MoonLake Immunotherapeutics MLTX
28 GF Score
Price $16.45
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Current Accrued Expense?

MoonLake Immunotherapeutics MLTX -0.24% 28 Current Accrued Expense is $22.15 Mil as of Jun. 2026. GuruFocus rates MLTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

MoonLake Immunotherapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $22.15 Mil.

MoonLake Immunotherapeutics's quarterly Current Accrued Expense increased from Dec. 2025 ($11.27 Mil) to Mar. 2026 ($18.22 Mil) and increased from Mar. 2026 ($18.22 Mil) to Jun. 2026 ($22.15 Mil).

MoonLake Immunotherapeutics's annual Current Accrued Expense increased from Dec. 2023 ($3.78 Mil) to Dec. 2024 ($7.22 Mil) and increased from Dec. 2024 ($7.22 Mil) to Dec. 2025 ($11.27 Mil).

MoonLake Immunotherapeutics Current Accrued Expense Related Terms

MoonLake Immunotherapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Current Accrued Expense Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
3.04 6.04 3.78 7.22 11.27

MoonLake Immunotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.66 16.37 11.27 18.22 22.15
MLTX
28GF Score
MoonLake Immunotherapeutics MLTX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $22.15 Mil mean?
MoonLake Immunotherapeutics (MLTX) has a Current Accrued Expense of $22.15 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on MoonLake Immunotherapeutics and its competitors.
Is MoonLake Immunotherapeutics' Current Accrued Expense too high?
MoonLake Immunotherapeutics' current Current Accrued Expense is $22.15 Mil. Overall, MoonLake Immunotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Current Accrued Expense compare to TSHA and INVA?
MoonLake Immunotherapeutics' Current Accrued Expense of $22.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current Current Accrued Expense is $22.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Current Accrued Expense of $22.15 Mil. The current Current Accrued Expense is $22.15 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Current Accrued Expense is $22.15 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
28GF Score

Get the complete analysis for MLTX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.45
Price